Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction

Jonathan Yap, Wan Ting Tay, Tiew-Hwa Katherine Teng, Inder Anand, A Mark Richards, Lieng Hsi Ling, Michael R MacDonald, Chanchal Chandramouli, Jasper Tromp, Bambang B Siswanto, ASIAN‐HF (Asian Sudden Cardiac Death in Heart Failure) Registry Investigators, Michael Zile, John McMurray, Carolyn S P Lam, Jonathan Yap, Wan Ting Tay, Tiew-Hwa Katherine Teng, Inder Anand, A Mark Richards, Lieng Hsi Ling, Michael R MacDonald, Chanchal Chandramouli, Jasper Tromp, Bambang B Siswanto, ASIAN‐HF (Asian Sudden Cardiac Death in Heart Failure) Registry Investigators, Michael Zile, John McMurray, Carolyn S P Lam

Abstract

Background Diabetes mellitus frequently coexists with heart failure (HF), but few studies have compared the associations between diabetes mellitus and cardiac remodeling, quality of life, and clinical outcomes, according to HF phenotype. Methods and Results We compared echocardiographic parameters, quality of life (assessed by the Kansas City Cardiomyopathy Questionnaire), and outcomes (1-year all-cause mortality, cardiovascular mortality, and HF hospitalization) between HF patients with and without type 2 diabetes mellitus in the prospective ASIAN-HF (Asian Sudden Cardiac Death in Heart Failure) Registry, as well as community-based controls without HF. Adjusted Cox proportional hazards models were used to assess the association of diabetes mellitus with clinical outcomes. Among 5028 patients with HF and reduced ejection fraction (HFrEF; EF <40%) and 1139 patients with HF and preserved EF (HFpEF; EF ≥50%), the prevalences of type 2 diabetes mellitus were 40.2% and 45.0%, respectively (P=0.003). In both HFrEF and HFpEF cohorts, diabetes mellitus (versus no diabetes mellitus) was associated with smaller indexed left ventricular diastolic volumes and higher mitral E/e' ratio. There was a predominance of eccentric hypertrophy in HFrEF and concentric hypertrophy in HFpEF. Patients with diabetes mellitus had lower Kansas City Cardiomyopathy Questionnaire scores in both HFpEF and HFrEF, with more prominent differences in HFpEF (Pinteraction<0.05). In both HFpEF and HFrEF, patients with diabetes mellitus had more HF rehospitalizations (adjusted hazard ratio, 1.27; 95% CI, 1.05-1.54; P=0.014) and higher 1-year rates of the composite of all-cause mortality/HF hospitalization (adjusted hazard ratio, 1.22; 95% CI, 1.05-1.41; P=0.011), with no differences between HF phenotypes (Pinteraction>0.05). Conclusions In HFpEF and HFrEF, type 2 diabetes mellitus is associated with smaller left ventricular volumes, higher mitral E/e' ratio, poorer quality of life, and worse outcomes, with several differences noted between HF phenotypes. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT01633398.

Keywords: diabetes mellitus; diabetic cardiomyopathy; echocardiography; heart failure; preserved left ventricular function.

Figures

Figure 1
Figure 1
Left ventricular geometry by heart failure (HF) type and type 2 diabetes mellitus (T2DM). HFpEF indicates HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction.
Figure 2
Figure 2
Survival by type 2 diabetes mellitus (DM) status for various outcomes at 1 year. HF indicates heart failure; HR, hazard ratio.

References

    1. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368:1681–1688.
    1. From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, Rodeheffer RJ, Roger VL. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006;119:591–599.
    1. Bank IEM, Gijsberts CM, Teng TK, Benson L, Sim D, Yeo PSD, Ong HY, Jaufeerally F, Leong GKT, Ling LH, Richards AM, de Kleijn DPV, Dahlstrom U, Lund LH, Lam CSP. Prevalence and clinical significance of diabetes in Asian versus white patients with heart failure. JACC Heart Fail. 2017;5:14–24.
    1. Cooper LB, Yap J, Tay WT, Teng TK, MacDonald M, Anand IS, Sharma A, O'Connor CM, Kraus WE, Mentz RJ, Lam CS. Multi‐ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF‐ACTION trial and the ASIAN‐HF registry. Eur J Heart Fail. 2018;20:1281–1289.
    1. Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two‐faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36:1718–1727, 1727a–1727c.
    1. Lam CS, Anand I, Zhang S, Shimizu W, Narasimhan C, Park SW, Yu CM, Ngarmukos T, Omar R, Reyes EB, Siswanto B, Ling LH, Richards AM. Asian sudden cardiac death in heart failure (ASIAN‐HF) registry. Eur J Heart Fail. 2013;15:928–936.
    1. Tromp J, Teng THK, Tay WT, Hung CL, Narasimhan C, Ngarmukos T, Reyes E, Siswanto B, Yu C, Zhang S, Yap J, MacDonald M, Leineweber K, Richards AM, Zile M, Anand I, Lam CSP. Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail. 2018;21:23–36.
    1. Santhanakrishnan R, Ng TP, Cameron VA, Gamble GD, Ling LH, Sim D, Leong GK, Yeo PS, Ong HY, Jaufeerally F, Wong RC, Chai P, Low AF, Lund M, Devlin G, Troughton R, Richards AM, Doughty RN, Lam CS. The Singapore heart failure outcomes and phenotypes (SHOP) study and prospective evaluation of outcome in patients with heart failure with preserved left ventricular ejection fraction (PEOPLE) study: rationale and design. J Card Fail. 2013;19:156–162.
    1. Lang RM, Badano LP, Mor‐Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233–270.
    1. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35:1245–1255.
    1. Eguchi K, Boden‐Albala B, Jin Z, Rundek T, Sacco RL, Homma S, Di Tullio MR. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol. 2008;101:1787–1791.
    1. Phillips RA, Krakoff LR, Dunaif A, Finegood DT, Gorlin R, Shimabukuro S. Relation among left ventricular mass, insulin resistance, and blood pressure in nonobese subjects. J Clin Endocrinol Metab. 1998;83:4284–4288.
    1. Hill DJ, Milner RD. Insulin as a growth factor. Pediatr Res. 1985;19:879–886.
    1. Straus DS. Growth‐stimulatory actions of insulin in vitro and in vivo. Endocr Rev. 1984;5:356–369.
    1. Ito H, Hiroe M, Hirata Y, Tsujino M, Adachi S, Shichiri M, Koike A, Nogami A, Marumo F. Insulin‐like growth factor‐I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation. 1993;87:1715–1721.
    1. Patil VC, Patil HV, Shah KB, Vasani JD, Shetty P. Diastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic function. J Cardiovasc Dis Res. 2011;2:213–222.
    1. Bayeva M, Sawicki KT, Ardehali H. Taking diabetes to heart—deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. J Am Heart Assoc. 2013;2:e000433 DOI: 10.1161/JAHA.113.000433.
    1. MacDonald MR, She L, Doenst T, Binkley PF, Rouleau JL, Tan RS, Lee KL, Miller AB, Sopko G, Szalewska D, Waclawiw MA, Dabrowski R, Castelvecchio S, Adlbrecht C, Michler RE, Oh JK, Velazquez EJ, Petrie MC. Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. Eur J Heart Fail. 2015;17:725–734.
    1. Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, Kober L, McKelvie RS, Zile MR, Anand IS, Komajda M, Gottdiener JS, Carson PE, McMurray JJ. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I‐Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017;135:724–735.
    1. Paulus WJ, Dal Canto E. Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction. JACC Heart Fail. 2018;6:1–7.
    1. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63:582–592.
    1. Kibel A, Selthofer‐Relatic K, Drenjancevic I, Bacun T, Bosnjak I, Kibel D, Gros M. Coronary microvascular dysfunction in diabetes mellitus. J Int Med Res. 2017;45:1901–1929.
    1. van Heerebeek L, Hamdani N, Handoko ML, Falcao‐Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbely A, van der Velden J, Stienen GJ, Laarman GJ, Niessen HW, Paulus WJ. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117:43–51.
    1. Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes. 2014;5:17–39.
    1. Pop‐Busui R, Cleary PA, Braffett BH, Martin CL, Herman WH, Low PA, Lima JAC, Bluemke DA; DCCT/EDIC Research Group . Association between cardiovascular autonomic neuropathy and left ventricular dysfunction: DCCT/EDIC study (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications). J Am Coll Cardiol. 2013;61:447–454.
    1. Tan ESJ, Tay WT, Teng THK, Sim D, Leong GKT, Yeo DPS, Ong HY, Jaufeerally F, Ng TP, Poppe K, Lund M, Devlin G, Troughton R, Ling LH, Richards AM, Doughty RN, Lam CSP. Ethnic differences in atrial fibrillation in patients with heart failure from Asia‐Pacific. Heart. 2018;105:842–847.
    1. Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, Hillege HL, Voors AA; BENEFICIAL Investigators . Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail. 2011;13:899–908.
    1. De Rango P, Farchioni L, Fiorucci B, Lenti M. Diabetes and abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2014;47:243–261.
    1. Lederle FA. The strange relationship between diabetes and abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 2012;43:254–256.
    1. Shapiro BP, Owan TE, Mohammed SF, Meyer DM, Mills LD, Schalkwijk CG, Redfield MM. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines. Circulation. 2008;118:1002–1010.
    1. Reddy HK, Koshy SK, Wasson S, Quan EE, Pagni S, Roberts AM, Joshua IG, Tyagi SC. Adaptive‐outward and maladaptive‐inward arterial remodeling measured by intravascular ultrasound in hyperhomocysteinemia and diabetes. J Cardiovasc Pharmacol Ther. 2006;11:65–76.
    1. Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, Schoenhagen P, Nissen SE. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol. 2008;52:255–262.
    1. Fujita B, Lauten A, Goebel B, Franz M, Fritzenwanger M, Ferrari M, Figulla HR, Kuethe F, Jung C. Impact of diabetes mellitus on quality of life in patients with congestive heart failure. Qual Life Res. 2012;21:1171–1176.
    1. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581–2587.
    1. Greenberg BH, Abraham WT, Albert NM, Chiswell K, Clare R, Stough WG, Gheorghiade M, O'Connor CM, Sun JL, Yancy CW, Young JB, Fonarow GC. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE‐HF). Am Heart J. 2007;154:277.e1–8.
    1. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in‐hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47:76–84.
    1. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ; CHARM Investigators . Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377–1385.
    1. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez‐Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I‐Preserve) trial. Circulation. 2010;121:1393–1405.
    1. Teng THK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, Wander G, Yap J, MacDonald M, Xu C, Shimizu W, Richards AM, Lam C. Prescribing patterns of evidence‐based heart failure pharmacotherapy and outcomes in the ASIAN‐HF registry: a cohort study. Lancet Glob Health. 2018;6:e1008–e1018.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir